Action 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zhejiang Ausun Pharmaceutical Co., Ltd.

Actions

603229

CNE100002XK2

Cours en clôture Shanghai S.E.
Autres places de cotation
 00:00:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
11,61 CNY +2,38% Graphique intraday de Zhejiang Ausun Pharmaceutical Co., Ltd. +16,92% -12,11%
26/04 Zhejiang Ausun Pharmaceutical Co. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI
26/04 Zhejiang Ausun Pharmaceutical Co. publie ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.
Ausun Pharma's Unit Passes Regulatory Inspection
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4%
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 603229
  4. Actualités Zhejiang Ausun Pharmaceutical Co., Ltd.
  5. Autres langues